188 related articles for article (PubMed ID: 19519771)
1. RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant.
Eckerich C; Schulte A; Martens T; Zapf S; Westphal M; Lamszus K
J Neurochem; 2009 May; 109(4):969-80. PubMed ID: 19519771
[TBL] [Abstract][Full Text] [Related]
2. Splice variants of the extracellular region of RON receptor tyrosine kinase in lung cancer cell lines identified by PCR and sequencing.
Krishnaswamy S; Mohammed AK; Tripathi G; Alokail MS; Al-Daghri NM
BMC Cancer; 2017 Nov; 17(1):738. PubMed ID: 29121914
[TBL] [Abstract][Full Text] [Related]
3. Identification of the splice variants of Recepteur d'Origine nantais (RON) in lung cancer cell lines.
Krishnaswamy S; Bukhari I; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Gene; 2018 Dec; 679():335-340. PubMed ID: 30223007
[TBL] [Abstract][Full Text] [Related]
4. The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells.
Feres KJ; Ischenko I; Hayman MJ
Oncogene; 2009 Jan; 28(2):279-88. PubMed ID: 18836480
[TBL] [Abstract][Full Text] [Related]
5. Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer.
Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Lung Cancer; 2016 Feb; 92():41-6. PubMed ID: 26775595
[TBL] [Abstract][Full Text] [Related]
6. A novel RON splice variant lacking exon 2 activates the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma cells.
Ling Y; Kuang Y; Chen LL; Lao WF; Zhu YR; Wang LQ; Wang D
Oncotarget; 2017 Jun; 8(24):39101-39116. PubMed ID: 28388571
[TBL] [Abstract][Full Text] [Related]
7. Activation of the RON receptor tyrosine kinase inhibits inducible nitric oxide synthase (iNOS) expression by murine peritoneal exudate macrophages: phosphatidylinositol-3 kinase is required for RON-mediated inhibition of iNOS expression.
Chen YQ; Fisher JH; Wang MH
J Immunol; 1998 Nov; 161(9):4950-9. PubMed ID: 9794431
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence.
Ma Q; Zhang K; Yao HP; Zhou YQ; Padhye S; Wang MH
Int J Oncol; 2010 Jun; 36(6):1551-61. PubMed ID: 20428780
[TBL] [Abstract][Full Text] [Related]
9. Characterization of two monoclonal antibodies against the RON tyrosine kinase receptor.
Montero-Julian FA; Dauny I; Flavetta S; Ronsin C; André F; Xerri L; Wang MH; Marvaldi J; Breathnach R; Brailly H
Hybridoma; 1998 Dec; 17(6):541-51. PubMed ID: 9890710
[TBL] [Abstract][Full Text] [Related]
10. Expression and mutational status of RON in neoplastic lesions of the breast: analysis of MSP/RON signaling in ductal carcinoma in situ and invasive ductal carcinoma.
Ren X; Daa T; Yada N; Kashima K; Fujitomi Y; Yokoyama S
APMIS; 2012 May; 120(5):358-67. PubMed ID: 22515290
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.
Camp ER; Yang A; Gray MJ; Fan F; Hamilton SR; Evans DB; Hooper AT; Pereira DS; Hicklin DJ; Ellis LM
Cancer; 2007 Mar; 109(6):1030-9. PubMed ID: 17311308
[TBL] [Abstract][Full Text] [Related]
12. Macrophage-stimulating protein and its receptor in non-small-cell lung tumors: induction of receptor tyrosine phosphorylation and cell migration.
Willett CG; Wang MH; Emanuel RL; Graham SA; Smith DI; Shridhar V; Sugarbaker DJ; Sunday ME
Am J Respir Cell Mol Biol; 1998 Apr; 18(4):489-96. PubMed ID: 9533936
[TBL] [Abstract][Full Text] [Related]
13. Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility.
Zhang K; Yao HP; Wang MH
Carcinogenesis; 2008 Mar; 29(3):552-9. PubMed ID: 18204077
[TBL] [Abstract][Full Text] [Related]
14. Expression of the receptor tyrosine kinase recepteur d'origine nantais and its association with tumor progression in hypopharyngeal cancer.
Yoon TM; Kim SA; Park YL; Lee KH; Sung MW; Lee JK; Lim SC; Chung IJ; Joo YE
Head Neck; 2013 Aug; 35(8):1106-13. PubMed ID: 22887469
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
Chao KL; Tsai IW; Chen C; Herzberg O
PLoS One; 2012; 7(7):e41912. PubMed ID: 22848655
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
17. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.
Xu XM; Wang D; Shen Q; Chen YQ; Wang MH
Oncogene; 2004 Nov; 23(52):8464-74. PubMed ID: 15378025
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder.
Cheng HL; Liu HS; Lin YJ; Chen HH; Hsu PY; Chang TY; Ho CL; Tzai TS; Chow NH
Br J Cancer; 2005 May; 92(10):1906-14. PubMed ID: 15870710
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein.
Chao KL; Gorlatova NV; Eisenstein E; Herzberg O
J Biol Chem; 2014 Oct; 289(43):29948-60. PubMed ID: 25193665
[TBL] [Abstract][Full Text] [Related]
20. Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers.
Wang MH; Yao HP; Zhou YQ
Acta Pharmacol Sin; 2006 Jun; 27(6):641-50. PubMed ID: 16723080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
